Update on Janus kinase antagonists in inflammatory bowel disease.


Janus kinase (JAK) inhibitors have emerged as a novel orally administered small-molecule therapy for the treatment of ulcerative colitis and possibly Crohn disease. These molecules are designed to selectively target the activity of specific JAKs and to offer a targeted mechanism of action without risk of immunogenicity. Based on data from clinical trials in rheumatoid arthritis and phase 2 studies in inflammatory bowel disease, tofacitinib and other JAK inhibitors are likely to become a new form of medical therapy for the treatment of inflammatory bowel disease.

DOI: 10.1016/j.gtc.2014.05.011
Citations per Year

Citation Velocity: 13

Averaging 13 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Boland2014UpdateOJ, title={Update on Janus kinase antagonists in inflammatory bowel disease.}, author={Brigid S. Boland and William J. Sandborn and John T. Chang}, journal={Gastroenterology clinics of North America}, year={2014}, volume={43 3}, pages={603-17} }